Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

HIV can be partially contained by host immunity and understanding the basis of this may inform vaccine design. The importance of B-cell function in long-term control is poorly understood. One method of investigating this is in vivo cellular depletion. In this study, we take advantage of a unique opportunity to investigate the role of B cells in an HIV-infected patient. The HIV-1(+) patient studied here was not taking antiretroviral drugs and was treated for pre-existing low-grade lymphoplasmacytoid lymphoma by depletion of CD20+ B cells using rituximab. We demonstrate that B-cell depletion results in a decline in autologous neutralizing antibody (NAb) responses and a 1.7 log(10) rise in HIV-1 plasma viral load (pVL). The recovery of NAbs results in a decline in pVL. The HIV-1 sequences diversify and NAb-resistant mutants are subsequently selected. These data suggest that B-cell function can contribute to the long-term control of pVL, and that NAbs may be more important in controlling chronic HIV-1 infection than previously suspected.

Original publication

DOI

10.1038/ncomms1100

Type

Journal article

Journal

Nat Commun

Publication Date

19/10/2010

Volume

1

Keywords

Antibodies, Monoclonal, Murine-Derived, Antibodies, Neutralizing, B-Lymphocytes, CD8-Positive T-Lymphocytes, Computational Biology, Enzyme-Linked Immunosorbent Assay, HIV Infections, Humans, Interferon-gamma, Molecular Sequence Data, Mutagenesis, Site-Directed, Rituximab